



MEDICAL TIPS

TENEBLU TABLETS

Issue IX, No. 34, 2022

Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study)

Bae JC et.al; Diabetes Metab J. 2022; 46: 81-92

- Teneligliptin is a potent and long-acting DPP-4 inhibitor, with well-recognized clinical efficacy and safety in the management of diabetes.
- In the present study, Teneligliptin or placebo was randomly assigned in a 1:1 ratio to elderly T2DM patients (N=65) aged ≥ 65 years for 12 weeks.
- Teneligliptin significantly reduced HbA1c (by 0.84%) at week 12 as compared to that in the placebo group (by 0.008%).
- Treatment with Teneligliptin resulted in significant improvement of glycemic variability (GV) & the time spent > 180 or 250 mg/dL, respectively, without increasing the time spent below 70 mg/dL as shown by continuous glucose-monitoring.

Treatment with Teneligliptin is effective and safe in improving HbA1c levels, target glucose range, and GV; and thus, it could be a good therapeutic choice for elderly patients with T2DM.

